Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | FPR1 | P21462 | 4/20 | 0.49 |
| ▸ | FPR2 | P25090 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685671 | 1.00 | SCN9A (0.51) | SCN9APABPC1FPR1FPR2CTSS | |
| SCHEMBL5960587 | 0.90 | SCN9A (0.48) | SCN9AFPR2CTSSCTSKCTSB | |
| SCHEMBL2686138 | 0.88 | SCN9A (0.47) | SCN9AFPR2CTSSCTSKCTSB | |
| SCHEMBL2686135 | 0.88 | SCN9A (0.47) | SCN9AFPR2CTSSCTSKCTSB | |
| SCHEMBL2685129 | 0.87 | FPR2 (0.54) | FPR1FPR2KMT2A | |
| SCHEMBL5960866 | 0.86 | SCN9A (0.48) | SCN9AFPR2CTSSCTSKCTSB | |
| SCHEMBL2684054 | 0.85 | FPR2 (0.57) | SCN9AFPR2CTSSCTSKCTSB | |
| SCHEMBL2684050 | 0.85 | FPR2 (0.57) | SCN9AFPR2CTSSCTSKCTSB | |
| SCHEMBL2374682 | 0.85 | SCN9A (0.61) | SCN9AFPR1FPR2CTSSCTSK | |
| SCHEMBL2374657 | 0.85 | SCN9A (0.61) | SCN9AFPR1FPR2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | SCN9A 2166/4885PABPC1 2132/4885FPR1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.